Despite financial constraints, AIM ImmunoTech Inc (AIM) progresses with promising clinical trials and strategic leadership ...

AstraZeneca PLC (NASDAQ:AZN)’s Q4 2024 financial results highlight robust growth despite some challenges. Total revenue for the year increased by 21%, driven by strong performances across all ...

AstraZeneca PLC (NASDAQ:AZN) is facing ongoing investigations in China regarding suspected unpaid importation taxes, which could result in significant fines. The company experienced a 3% decline in Q4 ...

Second, thanks to the progress of our collaboration with AstraZeneca. Up to year-end 2024, $47 million have been paid to Cellectis under the joint research and collaboration agreement of which $25 ...

AstraZeneca operates several segments focused on various therapeutic areas, and every one except "other medicines" saw sales move in the right direction in 2024. Even with the challenges that ...

CAMBRIDGE, Britain (AP) — CAMBRIDGE, Britain (AP) — Astrazeneca PLC (AZN) on Thursday reported fourth-quarter earnings of $1.5 billion. On a per-share basis, the Cambridge, Britain-based ...